Difference between revisions of "Stub"
Jump to navigation
Jump to search
Line 1: | Line 1: | ||
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the [[Ontology]]. | Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the [[Ontology]]. | ||
{{TOC limit|limit=2}} | {{TOC limit|limit=2}} | ||
+ | ==CE & Ipilimumab== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | CE & Ipilimumab: '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide, Ipilimumab | ||
+ | ===Regimen=== | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] | ||
+ | *[[Etoposide (Vepesid)]] | ||
+ | ====Immunotherapy==== | ||
+ | *[[Ipilimumab (Yervoy)]] | ||
+ | |||
==CE & Thalidomide== | ==CE & Thalidomide== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" |
Revision as of 02:06, 30 July 2020
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the Ontology.
CE & Ipilimumab
back to top |
CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab
Regimen
Chemotherapy
Immunotherapy
CE & Thalidomide
back to top |
CE & Thalidomide: Carboplatin, Etoposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
EP, Tamoxifen, RT
back to top |
EP, GM-CSF, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy
Regimen
Chemotherapy
Hormonotherapy
Radiotherapy
- Concurrent thoracic radiation therapy
Ixabepilone & Bevacizumab
back to top |
Regimen
Chemotherapy
Targeted therapy
TG+Bev
back to top |
TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
TX+Bev
back to top |
TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab